Luca Russolillo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Luca Russolillo has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Ingallinella
University of Parma Parma Italy
12 shared publications - Angela Celetti
CNR - Institute of Endotypes in Oncology, Metabolism and Immunology "G Salvatore" -IEOMI- Naples, Italy. Naples Italy
12 shared publications - Anna Spina
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Napoli Italy
12 shared publications - Benedetta Pellegrino
Medical Oncology and Breast Unit, University Hospital of Parma, 43126 Parma, Italy
12 shared publications - Camilla Nero
Unit of Oncological Gynecology, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy
12 shared publications - Carmela Baviello
University of Molise Campobasso Italy
12 shared publications
Latest Publications
- Open Access
- 19 December 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (1) , 201-210
CCDC6 immunostaining in conjunction with the Rad51 HRD assay may expand PARPi treatment eligibility in HGSOC patients.
HGSOC patients with BRCA1/2 mutations show HRD and PARPi sensitivity. Notably, HRD and PARPi response can occur without BRCA mutations, suggesting other factors are involved. Loss of CCDC6 function can lead to HRD and PARPi sensitivity in HGSOC cells, making CCDC6 a potential therapeutic target and biomarker. Three CCDC6 missense mutations in HGSOC prompted investigation into their impact on HRD. Analyzing CCDC6 expression, localization and HRD data in the MITO16A trial aims to clarify the CCDC6-HRD relationship in a large cohort. The biochemical and morphological effects of CCDC6 mutants on the native protein were examined using pull-down assays and immunofluorescence. HR-reporter and cell viability assays determined the impact of these mutants on HRD and PARPi sensitivity. CCDC6 histochemical score and intracellular-localization were assessed in MITO16A samples after immunostaining and digitalization. CCDC6-mutated isoforms act as dominant-negative, preventing native CCDC6 nuclear translocation, disrupting RAD51 foci and HR-repair, and increasing PARPi sensitivity. In the MITO16A patient sample set, 66 of 185 (35%) showed barely detectable CCDC6 or nuclear exclusion ("CCDC6-inactive"). CCDC6 impairment in these "CCDC6-inactive" samples was associated with HRD in 75% (30/40) of suitable samples analyzed by the RAD51 test and in 52% (34/65) of suitable samples analyzed by genomic HRD testing, even in the presence of wild-type BRCA1/BRCA2 genes. The association between CCDC6 inactivity and HRD, both at genomic and functional level, occurred even in presence of wild-type BRCA1/BRCA2 genes, suggesting that CCDC6 may play a crucial role in DNA repair pathways independent of these well-known genes.
- 19 December 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (1) , 201-210
Open AccessCCDC6 immunostaining in conjunction with the Rad51 HRD assay may expand PARPi treatment eligibility in HGSOC patients.
HGSOC patients with BRCA1/2 mutations show HRD and PARPi sensitivity. Notably, HRD and PARPi response can occur without BRCA mutations, suggesting other factors are involved. Loss of CCDC6 function can lead to HRD and PARPi sensitivity in HGSOC cells, making CCDC6 a potential therapeutic target and biomarker. Three CCDC6 missense mutations in HGSOC prompted investigation into their impact on HRD. Analyzing CCDC6 expression, localization and HRD data in the MITO16A trial aims to clarify the CCDC6-HRD relationship in a large cohort. The biochemical and morphological effects of CCDC6 mutants on the native protein were examined using pull-down assays and immunofluorescence. HR-reporter and cell viability assays determined the impact of these mutants on HRD and PARPi sensitivity. CCDC6 histochemical score and intracellular-localization were assessed in MITO16A samples after immunostaining and digitalization. CCDC6-mutated isoforms act as dominant-negative, preventing native CCDC6 nuclear translocation, disrupting RAD51 foci and HR-repair, and increasing PARPi sensitivity. In the MITO16A patient sample set, 66 of 185 (35%) showed barely detectable CCDC6 or nuclear exclusion ("CCDC6-inactive"). CCDC6 impairment in these "CCDC6-inactive" samples was associated with HRD in 75% (30/40) of suitable samples analyzed by the RAD51 test and in 52% (34/65) of suitable samples analyzed by genomic HRD testing, even in the presence of wild-type BRCA1/BRCA2 genes. The association between CCDC6 inactivity and HRD, both at genomic and functional level, occurred even in presence of wild-type BRCA1/BRCA2 genes, suggesting that CCDC6 may play a crucial role in DNA repair pathways independent of these well-known genes.
- Open Access
- 26 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Figure S1. Summary statistics of H-scores for protein localization categories.
- 26 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Figure S1. Summary statistics of H-scores for protein localization categories.
- Open Access
- 26 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Mutated isoforms of CCDC6 sensitize HGSOC cells to the PARPi olaparib alone or in combination with cisplatin. A–D, Drug sensitivity to olaparib or cisplatin has been evaluated by cell viability assay (CellTiter 96 Aqueous One Solution assay, Promega) in OVCAR3 and OV90 cell lines transfected with the myc-CCDC6 mutated isoforms L217P, A226S, and P442S or with the EV and exposed to the drug for 144 hours. The drug sensitivity is expressed as IC50 values. Statistical significance was verified by two-way ANOVA (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). E, The CI values according to the 1:2 concentration ratio of cisplatin and olaparib are shown (CI < 1, CI = 1, and CI > 1 indicate synergism, additive effect, and antagonism, respectively).
- 26 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Mutated isoforms of CCDC6 sensitize HGSOC cells to the PARPi olaparib alone or in combination with cisplatin. A–D, Drug sensitivity to olaparib or cisplatin has been evaluated by cell viability assay (CellTiter 96 Aqueous One Solution assay, Promega) in OVCAR3 and OV90 cell lines transfected with the myc-CCDC6 mutated isoforms L217P, A226S, and P442S or with the EV and exposed to the drug for 144 hours. The drug sensitivity is expressed as IC50 values. Statistical significance was verified by two-way ANOVA (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). E, The CI values according to the 1:2 concentration ratio of cisplatin and olaparib are shown (CI < 1, CI = 1, and CI > 1 indicate synergism, additive effect, and antagonism, respectively).
- Open Access
- 26 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Figure S2. IHC analysis of CCDC6 staining intensity and localization; CCDC6 expression evaluated by IHC compared to negative IgG control.
- 26 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Figure S2. IHC analysis of CCDC6 staining intensity and localization; CCDC6 expression evaluated by IHC compared to negative IgG control.
- Open Access
- 26 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Figure S3: (A) Immunofluorescence shows yH2AX nuclear foci formation in OVCAR3/OV90 cells after transfection with myc- CCDC6 mutated isoforms (A226S, L2 l 7P, P442S) or Empty Vector (EV) control and treatment with Etoposide [10 µM] for 8 hours. (B) Graphs display the percentage of cells with >5 foci (±SEM). (C-D) Western blots detect RAD5 l protein levels following transfection with CCDC6 mutated isoforms (C) or stable CCDC6 silencing (D) in OVCAR3/OV90 cells. Anti- Myc/Anti-CCDC6 and Anti-Tubulin were used as transfection/depletion and loading controls, respectively. (E-F) OVCAR3/OV90 cells, transfected with Myc-CCDC6 mutated isoforms/EV plus DR-GFP construct and I-Seel enzyme, were assessed for Homology-Directed Repair (HDR) efficiency (percentage of GFP positive cells, ±SEM).
- 26 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Figure S3: (A) Immunofluorescence shows yH2AX nuclear foci formation in OVCAR3/OV90 cells after transfection with myc- CCDC6 mutated isoforms (A226S, L2 l 7P, P442S) or Empty Vector (EV) control and treatment with Etoposide [10 µM] for 8 hours. (B) Graphs display the percentage of cells with >5 foci (±SEM). (C-D) Western blots detect RAD5 l protein levels following transfection with CCDC6 mutated isoforms (C) or stable CCDC6 silencing (D) in OVCAR3/OV90 cells. Anti- Myc/Anti-CCDC6 and Anti-Tubulin were used as transfection/depletion and loading controls, respectively. (E-F) OVCAR3/OV90 cells, transfected with Myc-CCDC6 mutated isoforms/EV plus DR-GFP construct and I-Seel enzyme, were assessed for Homology-Directed Repair (HDR) efficiency (percentage of GFP positive cells, ±SEM).
- Open Access
- 26 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Figure S5: Immunofluorescence images of OVCAR3 cells stably silenced for CCDC6 (shCCDC6) or control cells (shCTRL) transfected with the GFP vector (a-d) or the GFP-CCDC6 wild type (WT) co-transfected with the myc-tagged CCDC6 wild type (i-1), the mutated isoforms A226S, L217P and P442S expression vectors (m-x) or the empty vector (EV) as control (e-h). Nuclei are stained with Hoechst (Blue-channel). GFP-CCDC6 WT protein is shown in the green channel. The myc-tagged CCDC6 WT and mutated isoforms were visualized by the anti-myc antibody (red-channel).
- 26 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Figure S5: Immunofluorescence images of OVCAR3 cells stably silenced for CCDC6 (shCCDC6) or control cells (shCTRL) transfected with the GFP vector (a-d) or the GFP-CCDC6 wild type (WT) co-transfected with the myc-tagged CCDC6 wild type (i-1), the mutated isoforms A226S, L217P and P442S expression vectors (m-x) or the empty vector (EV) as control (e-h). Nuclei are stained with Hoechst (Blue-channel). GFP-CCDC6 WT protein is shown in the green channel. The myc-tagged CCDC6 WT and mutated isoforms were visualized by the anti-myc antibody (red-channel).
- Open Access
- 26 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Figure S4: (A) Levels of endogenous CCDC6, MycCCDC6 WT and mutated isoforms overexpression were assessed in OVCAR3 and OV90 cells by Western Blot using an anti-CCDC6 antibody. Tubulin is shown as loading control. (B) Levels ofMyc-CCDC6 WT and mutated isoforms overexpression and the degree of CCDC6 silencing were assessed in OVCAR3 and OV90 cells by Western Blot using an anti-CCDC6 antibody. Tubulin is shown as loading control. (C-D) Following treatment with Etoposide [10 µM] for 8 hours, cell viability was assessed in OVCAR3 and OV90 cells (C) as well as in OVCAR3 and OV90 cells stably silenced for CCDC6 (shCCDC6) (D) transfected with the myc-tagged CCDC6 wild type (WT), the mutated isoforms, A226S, L2l 7P and P442S expression vectors, or the empty vector (EV). Error bars indicate the standard error mean derived from three independent experiments.
- 26 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Figure S4: (A) Levels of endogenous CCDC6, MycCCDC6 WT and mutated isoforms overexpression were assessed in OVCAR3 and OV90 cells by Western Blot using an anti-CCDC6 antibody. Tubulin is shown as loading control. (B) Levels ofMyc-CCDC6 WT and mutated isoforms overexpression and the degree of CCDC6 silencing were assessed in OVCAR3 and OV90 cells by Western Blot using an anti-CCDC6 antibody. Tubulin is shown as loading control. (C-D) Following treatment with Etoposide [10 µM] for 8 hours, cell viability was assessed in OVCAR3 and OV90 cells (C) as well as in OVCAR3 and OV90 cells stably silenced for CCDC6 (shCCDC6) (D) transfected with the myc-tagged CCDC6 wild type (WT), the mutated isoforms, A226S, L2l 7P and P442S expression vectors, or the empty vector (EV). Error bars indicate the standard error mean derived from three independent experiments.
- Open Access
- 26 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
CCDC6 inactivation correlates with an HRD phenotype in patients with HGSOC. A, Representative images of IHC analysis of CCDC6 expression (a–c) and localization (d–f) in FFPE MITO16A patient samples (magnification 40×). The H-score values are listed as follows: a, (9); b, (50.68); c, (138.86); d, (149.61); e, (194.51); and f, (262.82). B, Summary of the MITO16A cases with CCDC6 inactivation, assessed for HRD test and/or RAD51 test and/or BRCA1/2 status. C, Causes of failure for the RAD51 assay in CCDC6 inactive samples. D, Percentages of Homologous Recombination Proficiency (HRP) and HRD tumors assessed by functional HRD testing among CCDC6 inactive MITO16A samples. E, Percentages of non-HRD and HRD tumors assessed by genomic HRD testing among CCDC6 inactive MITO16A samples. F, Percentage of BRCA1 and BRCA2 WT or mutated tumors among CCDC6-inactive MITO16A samples.
- 26 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
CCDC6 inactivation correlates with an HRD phenotype in patients with HGSOC. A, Representative images of IHC analysis of CCDC6 expression (a–c) and localization (d–f) in FFPE MITO16A patient samples (magnification 40×). The H-score values are listed as follows: a, (9); b, (50.68); c, (138.86); d, (149.61); e, (194.51); and f, (262.82). B, Summary of the MITO16A cases with CCDC6 inactivation, assessed for HRD test and/or RAD51 test and/or BRCA1/2 status. C, Causes of failure for the RAD51 assay in CCDC6 inactive samples. D, Percentages of Homologous Recombination Proficiency (HRP) and HRD tumors assessed by functional HRD testing among CCDC6 inactive MITO16A samples. E, Percentages of non-HRD and HRD tumors assessed by genomic HRD testing among CCDC6 inactive MITO16A samples. F, Percentage of BRCA1 and BRCA2 WT or mutated tumors among CCDC6-inactive MITO16A samples.
- Open Access
- 26 January 2026
- Published by American Association for Cancer Research (AACR)
Data from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Patients with high-grade serous ovarian carcinoma (HGSOC) with BRCA1/2 mutations show homologous recombination (HR) deficiency (HRD) and poly (ADP-ribose) polymerase inhibitors (PARPi) sensitivity. Notably, HRD and PARPi response can occur without BRCA mutations, suggesting that other factors are involved. Loss of coiled-coil domain containing 6 (CCDC6) function can lead to HRD and PARPi sensitivity in HGSOC cells, making CCDC6 a potential therapeutic target and biomarker. Three CCDC6 missense mutations in HGSOC prompted an investigation into their impact on HRD. Analyzing CCDC6 expression, localization, and HRD data in the MITO16A trial aims to clarify the CCDC6–HRD relationship in a large cohort. The biochemical and morphologic effects of CCDC6 mutants on the native protein were examined using pull-down assays and immunofluorescence. HR-reporter and cell viability assays determined the impact of these mutants on HRD and PARPi sensitivity. The CCDC6 histochemical score and intracellular localization were assessed in MITO16A samples after immunostaining and digitalization. CCDC6-mutated isoforms act as dominant-negative, preventing native CCDC6 nuclear translocation, disrupting RAD51 foci and HR repair, and increasing PARPi sensitivity. In the MITO16A patient sample set, 66 of 185 (35%) showed barely detectable CCDC6 or nuclear exclusion (“CCDC6-inactive”). CCDC6 impairment in these “CCDC6-inactive” samples was associated with HRD in 75% (30/40) of suitable samples analyzed by the RAD51 test and in 52% (34/65) of suitable samples analyzed by genomic HRD testing, even in the presence of wild-type (WT) BRCA1/BRCA2 genes. The association between CCDC6 inactivity and HRD, both at the genomic and functional levels, occurred even in the presence of WT BRCA1/BRCA2 genes, suggesting that CCDC6 may play a crucial role in DNA repair pathways independent of these well-known genes.Significance:In ovarian cancer, inactivation of the CCDC6 protein signals a defect in DNA repair, known as HRD. This finding might expand the pool of patients, including those who are BRCA WT, who can receive PARP inhibitors, significantly broadening access to this targeted, life-extending therapy.
- 26 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Patients with high-grade serous ovarian carcinoma (HGSOC) with BRCA1/2 mutations show homologous recombination (HR) deficiency (HRD) and poly (ADP-ribose) polymerase inhibitors (PARPi) sensitivity. Notably, HRD and PARPi response can occur without BRCA mutations, suggesting that other factors are involved. Loss of coiled-coil domain containing 6 (CCDC6) function can lead to HRD and PARPi sensitivity in HGSOC cells, making CCDC6 a potential therapeutic target and biomarker. Three CCDC6 missense mutations in HGSOC prompted an investigation into their impact on HRD. Analyzing CCDC6 expression, localization, and HRD data in the MITO16A trial aims to clarify the CCDC6–HRD relationship in a large cohort. The biochemical and morphologic effects of CCDC6 mutants on the native protein were examined using pull-down assays and immunofluorescence. HR-reporter and cell viability assays determined the impact of these mutants on HRD and PARPi sensitivity. The CCDC6 histochemical score and intracellular localization were assessed in MITO16A samples after immunostaining and digitalization. CCDC6-mutated isoforms act as dominant-negative, preventing native CCDC6 nuclear translocation, disrupting RAD51 foci and HR repair, and increasing PARPi sensitivity. In the MITO16A patient sample set, 66 of 185 (35%) showed barely detectable CCDC6 or nuclear exclusion (“CCDC6-inactive”). CCDC6 impairment in these “CCDC6-inactive” samples was associated with HRD in 75% (30/40) of suitable samples analyzed by the RAD51 test and in 52% (34/65) of suitable samples analyzed by genomic HRD testing, even in the presence of wild-type (WT) BRCA1/BRCA2 genes. The association between CCDC6 inactivity and HRD, both at the genomic and functional levels, occurred even in the presence of WT BRCA1/BRCA2 genes, suggesting that CCDC6 may play a crucial role in DNA repair pathways independent of these well-known genes.Significance:In ovarian cancer, inactivation of the CCDC6 protein signals a defect in DNA repair, known as HRD. This finding might expand the pool of patients, including those who are BRCA WT, who can receive PARP inhibitors, significantly broadening access to this targeted, life-extending therapy.